Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RAndomized pilot study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury

Next Previous
Trial Profile

A RAndomized pilot study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER 001 (Primary)
  • Indications Acute kidney injury
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RACERS STUDY
  • Sponsors ABIONYX Pharma

Most Recent Events

  • 24 Dec 2024 According to ABIONYX Pharma's media release, the company announced that the company's Phase 2b RACERS study in sepsis has been selected again as a poster presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week and Trials- Epidemiology and Pathophysiology poster session at the 2024 American Society of Nephrology Annual Meeting taking place October 23-27, 2024, in San Diego, California.
  • 13 Jun 2024 According to ABIONYX Pharma media release, Based on encouraging Phase 2a data and a productive pre-IND Type B meeting with U.S. Food and Drug Administration (FDA), ABIONYX Pharma intends to file an Investigational New Drug application (IND) in the coming months which will include a Phase 2b/3 clinical trial for CER001 in Sepsis.
  • 16 Nov 2023 According to an ABIONYX Pharma media release, the full results of the RACERS study were published simultaneously and exclusively in the journal BMC Medicine (Nature Springer).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top